Cutler Group’s Cabaletta Bio CABA Stock Holding History

Cutler Group’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-300	Closed	-$3K	–	2395
2023 Q4	$3K	Buy	+300	New	+$5.04K	﹤0.01%	2921

Other funds holding CABA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Cutler Group's CABA Position: Q4 2022 in Review

Cutler Group sold out of Cabaletta Bio (CABA) in Q4 2022, closing a stake of 600 shares.

Cutler Group first reported a position in CABA in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 61 funds tracked by Wall St. Rank hold CABA as of Q4 2022.

Cutler Group reported no remaining Cabaletta Bio position as of Q4 2022 after selling out during the quarter.
Cutler Group sold 600 Cabaletta Bio shares in Q4 2022.
Cutler Group first reported a position in Cabaletta Bio in Q3 2022 and held it in 1 quarter.
Cutler Group's Cabaletta Bio position peaked at $0 in Q3 2022.
61 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.